decisionhealth Newsletters, Part B News - 2007 Issue 5 (May)
IVIG a losing proposition for many physicians, OIG reports
Subscribe or sign in to view the full article.
Article Overview
This article reviews Medicare reimbursement issues tied to intravenous immune globulin (IVIG) in physician-office settings, drawing on an HHS Office of Inspector General report and patient advocacy perspectives. It covers payment trends, temporary CMS payment adjustments, office-based billing activity, and broader access concerns affecting patients and practices. It is relevant to physicians, coders, billing staff, and policy analysts who follow drug administration reimbursement and site-of-care shifts.
Why This Topic Matters
The piece helps readers understand why IVIG administration has become financially difficult for many physician practices and why payment policy changes can affect where patients receive infusion therapy. It is useful for evaluating reimbursement trends, reporting context, and the operational impact of Medicare payment updates.
What You Will Learn
- How IVIG reimbursement trends have affected physician-office administration
- What the article says about Medicare payment adequacy and practice costs
- How temporary CMS payment adjustments are discussed in relation to IVIG
- Why site-of-care changes are a concern for patients and practices
- Which organizations and advocacy perspectives are referenced in the discussion
Who Should Read This
- Physicians
- Medical coders
- Billing and reimbursement staff
- Practice administrators
- Health policy analysts
- Patient advocacy stakeholders
Codes Discussed
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com